相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
Michelle A. Maynard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis
Tomohiro Funakoshi et al.
ACTA ONCOLOGICA (2013)
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D. W. Miles et al.
BRITISH JOURNAL OF CANCER (2013)
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2013)
Targeted inhibition of VEGF receptor 2: an update on ramucirumab
Jeffrey Melson Clarke et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition
Kevin Wei et al.
NATURE MEDICINE (2013)
Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes
Cullen M. Taniguchi et al.
NATURE MEDICINE (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues
Yunlong Yanga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inappropriate heat dissipation ignites brown fat thermogenesis in mice with a mutant thyroid hormone receptor α1
Amy Warner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Reduction in Thyroid Perfusion After Bevacizumab Treatment
Astrid A. M. van der Veldt et al.
THYROID (2013)
Paraneoplastic symptoms: Cachexia, polycythemia,, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma
Guan-xiong Ding et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment
Hala Ahmadieh et al.
BIOMED RESEARCH INTERNATIONAL (2013)
Norrin/Frizzled4 Signaling in Retinal Vascular Development and Blood Brain Barrier Plasticity
Yanshu Wang et al.
CELL (2012)
A Case of Acute Adrenal Insufficiency Unmasked During Sunitinib Treatment for Metastatic Renal Cell Carcinoma
Takayuki Yoshino et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
Doreen Braun et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells
Yuan Xue et al.
NATURE MEDICINE (2012)
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Harry D. Bear et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Barrier Within: Endothelial Transport of Hormones
Cathryn M. Kolka et al.
PHYSIOLOGY (2012)
Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis
Renhai Cao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
Mariette H. W. Kappers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Changing End Points in Breast-Cancer Drug Approval - The Avastin Story
Ralph B. D'Agostino
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety of Bevacizumab in Patients with Metastatic Breast Cancer
Erika P. Hamilton et al.
ONCOLOGY (2011)
Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity
Danfang Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Connective tissue growth factor acts within both endothelial cells and β cells to promote proliferation of developing β cells
Michelle A. Guney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Off-tumor target-beneficial site for antiangiogenic cancer therapy?
Yihai Cao
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Lorraine C. Pelosof et al.
MAYO CLINIC PROCEEDINGS (2010)
Quantifying the Proteolytic Release of Extracellular Matrix-Sequestered VEGF with a Computational Model
Prakash Vempati et al.
PLOS ONE (2010)
Optimizing the Delivery of Cancer Drugs that Block Angiogenesis
Yihai Cao et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
How Does Sunitinib Cause Hypothyroidism?
Jerome M. Hershman et al.
THYROID (2010)
Hester van Cruijsen, Astrid van der Veldt, Klaas Hoekman
Hester van Cruijsen et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2009)
Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model
Samantha Lin Chiou Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Yihai Cao
SCIENCE SIGNALING (2009)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome
Yuan Xue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Effect of sunitinib on growth and function of FRTL-5 thyroid cells
Andrew K. Salem et al.
THYROID (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Anti-PIGF inhibits growth of VEGF(R)-Inhibitor-Resistant tumors without affecting healthy vessels
Christian Fischer et al.
CELL (2007)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
John M. L. Ebos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Molecular regulation of angiogenesis and lymphangiogenesis
Ralf H. Adams et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Islet vasculature as a regulator of endocrine pancreas function
Nikiforos Ballian et al.
WORLD JOURNAL OF SURGERY (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
Edwin P. Rock et al.
ONCOLOGIST (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma
Christian A. Koch et al.
BMC CANCER (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Tumor angiogenesis and therapy
Y Cao
BIOMEDICINE & PHARMACOTHERAPY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Opinion - Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis
YH Cao
NATURE REVIEWS CANCER (2005)
Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours
AM Jubb et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability
RH Cao et al.
CIRCULATION RESEARCH (2004)
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G Bocci et al.
CANCER RESEARCH (2004)
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization
J LeCouter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia
H Gerhardt et al.
JOURNAL OF CELL BIOLOGY (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Small GTP-binding protein Rac is an essential mediator of vascular endothelial growth factor-induced endothelial fenestrations and vascular permeability
A Eriksson et al.
CIRCULATION (2003)
Perlecan and tumor angiogenesis
XN Jiang et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2003)
Lymphangiogenesis and cancer metastasis
SA Stacker et al.
NATURE REVIEWS CANCER (2002)
Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea
H Kubo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Y Makino et al.
NATURE (2001)
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
D Lyden et al.
NATURE MEDICINE (2001)
Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome
AK Wong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The VEGF splice variants: Properties, receptors, and usage for the treatment of ischemic diseases
Z Poltorak et al.
HERZ (2000)
分享论文
